George A. Fisher Jr.

Medical oncologist

GI specialist
I conduct clinical research on a variety of gastrointestinal cancers and provide care for patients with those cancers. We have trials of combined modality therapy (surgery +/- radiation +/- chemotherapy) on gastric, esophageal, pancreas and rectal cancers. We also perform phase I and II trials of biologically targeted agents as well as newer immunotherapeutics. In collaboration with a number of colleagues, we conduct translational studies analyzing novel imaging (e.g. contrast enhanced ultrasound and perfusion scans) and molecular biomarkers. Neuroendocrine tumors, pancreas, colorectal and gastro-esophageal cancers have been areas of particular research focus with multiple therapeutic and translational studies devote to each. Examples of recently completed trials include a randomized phase III trial of a vaccine (algenpantucel) for resected pancreas cancer, phase Ib trial of anti-PD-L1 and separate phase II trials using chemotherapy with angiogenesis inhibitors for advanced neuroendocrine tumors and gastro-esophageal adenocarcinomas. Currently active areas of study include combining immunomodulating antibodies against checkpoint inhibitors and a trial of an antibody to interleukin 1 for colorectal cancer. Participation and leadership in NCI cooperative group protocols gives our patients access to the randomized trials that hope to establish new standards of care for a variety of GI cancers.

Gastrointestinal (GI) Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Fellowship: Stanford University Medical Center (1993) CA

Residency: Stanford University Medical Center (1989) CA

Internship: Stanford University Medical Center (1988) CA

Medical Education: Stanford University School of Medicine (1987) CA

BS, Stanford University, Biology (1976)

PhD, Stanford University, Cancer Biology (1987)

MD, Stanford University, Medicine (1987)

Residency, Stanford University, Internal Medicine (1989)

Fellowship, Stanford University, Medical Oncology (1993)

Administrative Appointments

Physician Leader, GI Clinical Research Group, 2010

Director, Cancer Clinical Trials Office, 2004

Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?
Patel, M. I., Rhoads, K. F., Ma, Y., Ford, J. M., Visser, B. C., & Poultsides, G. A. (2013). Seventh Edition (2010) of the AJCC/UICC Staging System for Gastric Adenocarcinoma: Is there Room for Improvement?. ANNALS OF SURGICAL ONCOLOGY, 20(5), 1631-1638.

Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process
Strosberg, J. R., Fisher, G. A., Benson, A. B., Malin, J. L., Cherepanov, D., & Broder, M. S. (2013). Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors Consensus Results From a Modified Delphi Process. PANCREAS, 42(3), 397-404.

Capecitabine-Induced Chest Pain Relieved by Diltiazem
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623-1626.

Long-Term Survivors of Gastric Cancer: A California Population-Based Study
Kunz, P. L., Gubens, M., Fisher, G. A., Ford, J. M., Lichtensztajn, D. Y., & Clarke, C. A. (2012). Long-Term Survivors of Gastric Cancer: A California Population-Based Study. JOURNAL OF CLINICAL ONCOLOGY, 30(28), 3507-3515.

Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features
Chang, D. T., Pai, R. K., Rybicki, L. A., DiMaio, M. A., Limaye, M., & Pai, R. K. (2012). Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. MODERN PATHOLOGY, 25(8), 1128-1139.

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis
Poultsides, G. A., Huang, L. C., Chen, Y., Visser, B. C., Pai, R. K., & Norton, J. A. (2012). Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis. ANNALS OF SURGICAL ONCOLOGY, 19(7), 2295-2303.

A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
Cabebe, E. C., Fisher, G. A., & Sikic, B. I. (2012). A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 30(3), 1082-1087.

A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
Padda, S. K., Krupitskaya, Y., Chhatwani, L., Fisher, G. A., Colevas, A. D., & Wakelee, H. A. (2012). A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 69(4), 1013-1020.

Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma
Abelson, J. A., Murphy, J. D., Minn, A. Y., Chung, M., Fisher, G. A., & Chang, D. T. (2012). Intensity-Modulated Radiotherapy for Pancreatic Adenocarcinoma. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 82(4), E595-E601.

HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment
Kunz, P. L., Mojtahed, A., Fisher, G. A., Ford, J. M., Chang, D. T., & Pai, R. K. (2012). HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population: Clinicopathologic Analysis With Proposed Approach to HER2 Assessment. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 20(1), 13-24.

Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies
Galatin, P. S., Advani, R. H., Fisher, G. A., Francisco, B., Julian, T., & Sikic, B. I. (2011). Phase I trial of oblimersen (GenasenseA (R)) and gemcitabine in refractory and advanced malignancies. INVESTIGATIONAL NEW DRUGS, 29(5), 971-977.

Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal
Bazan, J. G., Hara, W., Hsu, A., Kunz, P. A., Ford, J., & Chang, D. T. (2011). Intensity-Modulated Radiation Therapy Versus Conventional Radiation Therapy for Squamous Cell Carcinoma of the Anal Canal. CANCER, 117(15), 3342-3351.

Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection
Norton, J. A., Harris, E. J., Chen, Y., Visser, B. C., Poultsides, G. A., & Jensen, R. T. (2011). Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for Resection. ARCHIVES OF SURGERY, 146(6), 724-732.

F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases
Zissen, M. H., Kunz, P., Subbarayan, M., Chin, F. T., Conti, P. S., & Quon, A. (2011). F-18-5-fluorouracil dynamic positron emission tomography/computed tomography shows decreased tracer activity after bevacizumab in colorectal metastases. NUCLEAR MEDICINE COMMUNICATIONS, 32(5), 343-347.

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting
Kulke, M. H., Siu, L. L., Tepper, J. E., Fisher, G., Jaffe, D., & Yao, J. C. (2011). Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. JOURNAL OF CLINICAL ONCOLOGY, 29(7), 934-943.

Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma
Chang, D. T., Chapman, C. H., Norton, J. A., Visser, B., Fisher, G. A., & Pai, R. K. (2010). Expression of p16(INK4A) But Not Hypoxia Markers or Poly Adenosine Diphosphate-Ribose Polymerase Is Associated With Improved Survival in Patients With Pancreatic Adenocarcinoma. CANCER, 116(22), 5179-5187.

Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer
Minn, A. Y., Hsu, A., La, T., Kunz, P., Fisher, G. A., & Chang, D. T. (2010). Comparison of Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy as Adjuvant Therapy for Gastric Cancer. CANCER, 116(16), 3943-3952.

Pathological response after chemoradiation for T3 rectal cancer.
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. Colorectal disease , 12(7 Online), e24-30.

Pathological response after chemoradiation for T3 rectal cancer
Chennupati, S. K., Kamaya, A., Fisher, G. A., Ford, J. M., Kunz, P., & Chang, D. T. (2010). Pathological response after chemoradiation for T3 rectal cancer. COLORECTAL DISEASE, 12(7), E24-E30.

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
Wakelee, H. A., Patnaik, A., Sikic, B. I., Mita, M., Fox, N. L., & Tolcher, A. W. (2010). Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. ANNALS OF ONCOLOGY, 21(2), 376-381.

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
Kunz, P. L., & Fisher, G. A. (2010). Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical and experimental gastroenterology, 3, 79-86.

Multimodality treatment with intensity modulated radiation therapy for esophageal cancer
La, T. H., Minn, A. Y., Su, Z., Fisher, G. A., Ford, J. M., & Chang, D. T. (2010). Multimodality treatment with intensity modulated radiation therapy for esophageal cancer. DISEASES OF THE ESOPHAGUS, 23(4), 300-308.

Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis
Chang, S. T., Zahn, J. M., Horecka, J., Kunz, P. L., Ford, J. M., & Koong, A. C. (2009). Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis. JOURNAL OF TRANSLATIONAL MEDICINE, 7.

Impaired interferon signaling is a common immune defect in human cancer
Critchley-Thorne, R. J., Simons, D. L., Yan, N., Miyahira, A. K., Dirbas, F. M., & Lee, P. P. (2009). Impaired interferon signaling is a common immune defect in human cancer. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 106(22), 9010-9015.

Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas
Chang, D. T., Schellenberg, D., Shen, J., Kim, J., Goodman, K. A., & Koong, A. C. (2009). Stereotactic Radiotherapy for Unresectable Adenocarcinoma of the Pancreas. CANCER, 115(3), 665-672.

Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer
Schellenberg, D., Goodman, K. A., Lee, F., Chang, S., Kuo, T., & Koong, A. C. (2008). Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 72(3), 678-686.

A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer
Fischer, Ga., Kuo, T., Ramsey, M., Schwartz, E., Rouse, Rv., & Sikic, B. I. (2008). A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. CLINICAL CANCER RESEARCH, 14(21), 7074-7079.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613-1618.

Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies
Cupp, J. S., Koong, A. C., Fisher, G. A., NORTON, J. A., & Goodman, K. A. (2008). Tissue effects after stereotactic body radiotherapy using cyberknife for patients with abdominal malignancies. CLINICAL ONCOLOGY, 20(1), 69-75.

Phase H study of imatinib in unresectable hepatocellular carcinoma
Lin, A. Y., Fisher, G. A., So, S., Tang, C., & Levitt, L. (2008). Phase H study of imatinib in unresectable hepatocellular carcinoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 31(1), 84-88.

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
Demetri, G. D., Benjamin, R. S., Blanke, C. D., Blay, J.-Y., Casali, P., & Zalcberg, J. (2007). NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network , 5, S1-29.

Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer
Cabebe, E., & Fisher, G. A. (2007). Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 16(4), 467-476.

Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer
Street, H. H., Goris, M. L., Fisher, G. A., Wessels, B. W., Cho, C., & Knox, S. J. (2006). Phase I study of I-131-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 21(3), 243-256.

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies
Cho, C. D., Fisher, G. A., Halsey, J., & Sikic, B. I. (2006). Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. INVESTIGATIONAL NEW DRUGS, 24(2), 117-123.

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., & Sikic, B. I. (2005). A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. ANNALS OF ONCOLOGY, 16(12), 1968-1973.

Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
Kuo, T., & Fisher, G. A. (2005). Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer. Clinical colorectal cancer, 5, S62-70.

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer
Advani, R., Lum, B. L., Fisher, G. A., Halsey, J., Geary, R. S., & Sikic, B. I. (2005). A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer. INVESTIGATIONAL NEW DRUGS, 23(5), 467-477.

Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer
Koong, A. C., Christofferson, E., Le, Q. T., Goodman, K. A., Ho, A., & Yang, G. P. (2005). Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 63(2), 320-323.

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer
Kuo, T., Cho, C. D., Halsey, J., Wakelee, H. A., Advani, R. H., & Sikic, B. I. (2005). Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 23(24), 5613-5619.

A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer
Wakelee, H., & Fisher, G. A. (2005). A phase I trial of irinotecan (CPT-11) with amifostine in patients with metastatic colorectal cancer. INVESTIGATIONAL NEW DRUGS, 23(3), 241-242.

Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma
Lin, A. Y., Brophy, N., Fisher, G. A., So, S., Biggs, C., & Levitt, L. (2005). Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. CANCER, 103(1), 119-125.

Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer
Koong, A. C., Le, Q. T., Ho, A., Fong, B., Fisher, G., & Bastidas, J. A. (2004). Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 58(4), 1017-1021.

A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma
Advani, R., Peethambaram, P., Lum, B. L., Fisher, G. A., Hartmann, L., & Sikic, B. I. (2004). A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. CANCER, 100(2), 321-326.

A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer.
Cho, C. D., Fisher, G. A., Halsey, J., Jambalos, C. N., Schwartz, E. J., & Sikic, B. I. (2003). A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. CLINICAL CANCER RESEARCH, 9(16), 6103S-6103S.

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies
Advani, R., Fisher, G. A., Lum, B. L., Jambalos, C., Cho, C. D., & Sikic, B. I. (2003). Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. CLINICAL CANCER RESEARCH, 9(14), 5187-5194.

Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer
Mehta, V. K., Cho, C., Ford, J. M., Jambalos, C., Poen, J., & Fisher, G. (2003). Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 55(1), 132-137.

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y. F., Rivas, A., Benike, C., Yuen, A., & Engleman, E. G. (2001). Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 98(15), 8809-8814.

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Advani, R., Fisher, G. A., Lum, B. L., Hausdorff, J., Halsey, J., & Sikic, B. I. (2001). A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. CLINICAL CANCER RESEARCH, 7(5), 1221-1229.

Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer
Mehta, V. K., Poen, J. C., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Fisher, G. A. (2001). Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 24(2), 155-159.

Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis
Lai, K. M., MILLAN, M., Razavi, M., Keeffe, E. B., Prapong, W., & So, S. Ks. (2001). Center experience in liver transplantation for hepatocellular carcinoma associated with cirrhosis. TRANSPLANTATION PROCEEDINGS, 33(1-2), 1490-1491.

Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas
Mehta, V. K., Fisher, G., Ford, J. A., Poen, J. C., Vierra, M. A., & Bastidas, J. A. (2001). Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. JOURNAL OF GASTROINTESTINAL SURGERY, 5(1), 27-35.

Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer
Mehta, V. K., Poen, J., Ford, J., Edelstein, P. S., Vierra, M., & Fisher, G. (2001). Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer. DISEASES OF THE COLON & RECTUM, 44(1), 52-58.

Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report
Mehta, V. K., Fisher, G. A., Ford, J. M., Poen, J. C., Vierra, M. A., & Bastidas, A. J. (2001). Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of vater - Preliminary report. ARCHIVES OF SURGERY, 136(1), 65-69.

Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer
Mehta, V. K., Fisher, G. A., Ford, J. M., Oberhelman, H. A., Vierra, M. A., & Poen, J. C. (2000). Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(5), 1483-1487.

Pancreatic tumors show high levels of hypoxia
Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., & Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 48(4), 919-922.

Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance
Lum, B. L., Kaubisch, S., Fisher, G. A., Brown, B. W., & Sikic, B. I. (2000). Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 45(4), 305-311.

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer
Yuen, A. R., Halsey, J., Fisher, G. A., Holmlund, J. T., Geary, R. S., & Sikic, B. I. (1999). Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer. CLINICAL CANCER RESEARCH, 5(11), 3357-3363.

Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil
Poen, J. C., Collins, H. L., Niederhuber, J. E., Oberhelman, H. A., Vierra, M. A., & Goffinet, D. R. (1998). Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 40(1), 93-99.

Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
Sikic, B. I., Fisher, G. A., Lum, B. L., Halsey, J., BEKETICORESKOVIC, L., & Chen, G. (1997). Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 40, S13-S19.

Pharmacological considerations in the modulation of multidrug resistance
Fisher, G. A., Lum, B. L., Hausdorff, J., & Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance. EUROPEAN JOURNAL OF CANCER, 32A(6), 1082-1088.

Drug resistance in clinical oncology and hematology. Introduction.
Fisher, G. A., & Sikic, B. I. (1995). Drug resistance in clinical oncology and hematology. Introduction. Hematology/oncology clinics of North America, 9(2), xi-xii.

CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE
Fisher, G. A., & Sikic, B. I. (1995). CLINICAL-STUDIES WITH MODULATORS OF MULTIDRUG-RESISTANCE. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 9(2), 363-382.

The reversal of multidrug resistance.
Fisher, G. A., Lum, B. L., & Sikic, B. I. (1995). The reversal of multidrug resistance. Cancer treatment and research, 78, 45-70.

MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG)
Li, G. C., Fessenden, P., Hahn, G. M., Fisher, G., Luxton, G., & Bagshaw, M. A. (1994). MAMMALIAN-CELL SURVIVAL STUDIES CHARACTERIZING MULTIPORT NEGATIVE PI-MESON IRRADIATION WITH THE STANFORD MEDICAL PION GENERATOR (SMPG). INTERNATIONAL JOURNAL OF HYPERTHERMIA, 10(3), 361-370.

PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE
Bartlett, N. L., Lum, B. L., Fisher, G. A., BROPHY, N. A., EHSAN, M. N., & Sikic, B. I. (1994). PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 12(4), 835-842.

Clinical reversal of multidrug resistance.
Sikic, B. I., Fisher, G. A., Lum, B. L., BROPHY, N. A., Yahanda, A. M., & Halsey, J. (1994). Clinical reversal of multidrug resistance. Cancer treatment and research, 73, 149-165.

CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS
Lum, B. L., Fisher, G. A., BROPHY, N. A., Yahanda, A. M., ADLER, K. M., & Sikic, B. I. (1993). CLINICAL-TRIALS OF MODULATION OF MULTIDRUG-RESISTANCE - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS. CANCER, 72(11), 3502-3514.

THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD
Fisher, G. A., BROPHY, N. A., Yahanda, A. M., Adler, K. A., Lum, B. L., & Sikic, B. I. (1993). THE MODULATION OF MULTIDRUG-RESISTANCE - CLINICAL-STUDIES AT STANFORD. ELSEVIER SCIENCE PUBL B V.

PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE
Yahanda, A. M., ADLER, K. M., Fisher, G. A., BROPHY, N. A., Halsey, J., & Sikic, B. I. (1992). PHASE-I TRIAL OF ETOPOSIDE WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG RESISTANCE. JOURNAL OF CLINICAL ONCOLOGY, 10(10), 1624-1634.

DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS
Anderson, R. L., Shiu, E., Fisher, G. A., & Hahn, G. M. (1988). DNA DAMAGE DOES NOT APPEAR TO BE A TRIGGER FOR THERMOTOLERANCE IN MAMMALIAN-CELLS. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 54(2), 285-298.

CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING
RICE, G. C., Fisher, K. A., Fisher, G. A., & Hahn, G. M. (1987). CORRELATION OF MAMMALIAN-CELL KILLING BY HEAT-SHOCK TO INTRAMEMBRANOUS PARTICLE AGGREGATION AND LATERAL PHASE-SEPARATION USING FLUORESCENCE-ACTIVATED CELL SORTING. RADIATION RESEARCH, 112(2), 351-364.